The Use of PSMA Targeted Therapy and Hormone Therapy in Renally Impaired Patient

Nat Lenzo, MMed MSc(Oncol) EMBA FRACP FAANMS; Jaideep S. Sohi, MD


Appl Radiol. 2021;50(5):40-43. 

In This Article

Case Summary

An 82-year-old man presented with rising PSA of 21 ng/ml in July 2015. Prior to this time, in 2008, he received androgen deprivation therapy (ADT) and prostatic bed radiation (74 Gy). Patient was in Grade III renal failure with an eGFR of 30–40 ml/min and had previously undergone a laminectomy along with a history of osteoarthritis and lumbar stenosis.

In August 2015, the patient underwent a bone scan, which only detected degenerative changes. A CT scan found no evidence of metastatic disease. However, slightly prominent pelvic nodes of uncertain significance were noted and further evaluated with a 68-gallium (68Ga) PSMA-11 PET scan in September 2015. At the time of the PSMA PET scan, his PSA had risen to 29 ng/ml; it increased to 40 ng/ml the following month. At this time, the eGFR was 35 ml/min.